; and (2) in paragraph (2)— (A) by striking 4,000 and inserting 6,500 ; and (B) by striking 2020 and inserting 2022 . (b) Updated evaluation and report Section 101(f) is amended— (1) by redesignating paragraph (2) as paragraph (3); and (2) by inserting after paragraph (1) the following new paragraph: (2) Updated evaluation and report Not later than one year after the date of the enactment of the Continuing Access to In-Home IVIG Act, the Secretary shall submit to Congress an updated report that contains the following: (A) The total number of beneficiaries enrolled in the demonstration project during the updated report period. (B) The total number of claims submitted for services during the updated report period, disaggregated by month. (C) An analysis of the impact of the demonstration on beneficiary access to the in-home administration of intravenous immune globin, including the impact on beneficiary health and well-being. (D) An analysis of the impact of in-home administration of intravenous immune globin on overall costs to Medicare, including the cost differential between in-home administration of intravenous immune globin and administration of intravenous immune globin in a healthcare facility. (E) A survey of providers and enrolled beneficiaries that participated in the demonstration project that identifies barriers to accessing services, including reimbursement for items and services. (F) Recommendations to Congress on the appropriateness of establishing a permanent bundled services payment for the in-home administration of intravenous immune globin for Medicare beneficiaries. . (c) Definition of updated report period Section 101(h) is amended by adding at the end the following new paragraph: (4) Updated report period The term updated report period means the period beginning on October 1, 2014, and ending on September 30, 2020. .